Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ZB-106
Tibulizumab · 2 trials · 3 indications
AN count is calculated based on the sum of the abscesses and inflammatory nodules across different anatomical areas
The mRSS assesses skin thickness at 17 different cutaneous sites across the body using a scale from 0 (normal skin) to 3 (severe thickening), with a total score ranging from 0 (no thickening) to 51 (severe thickening in all 17 areas)
Assessed by the incidence of all treatment-emergent adverse events (TEAEs), as well as changes from baseline in vital signs, electrocardiogram (ECG) parameters, and laboratory results
| Arm | Type | Description |
|---|---|---|
| Tibulizumab Dose A | EXPERIMENTAL | Subcutaneous injection |
| Tibulizumab Dose B | EXPERIMENTAL | Subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous injection |
| Tibulizumab | EXPERIMENTAL | Subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Tibulizumab Dose A | BIOLOGICAL | Anti BAFF/IL-17 antibody. ZB-106 |
| Tibulizumab Dose B | BIOLOGICAL | Anti BAFF/IL-17 antibody. ZB-106 |
| Placebo | OTHER | ZB-106 Placebo |
| Tibulizumab | BIOLOGICAL | Anti BAFF/IL-17 antibody |
Inclusion Criteria: * Male or female, 18 to 70 years of age * ≥6-month history of Hidradenitis suppurativa (HS) * Total AN (abscess and inflammatory nodule) count ≥5 * HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage II or III Exclusion Criteria: * Draining tunnel...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib, Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | povorcitinib, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Remibrutinib, Secukinumab |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE2 | Duvakitug, Brivekimig, SAR445399 |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Olatorepatide |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY072 |
| Oruka Therapeutics, Inc. | ORKA | 1 | PHASE2 | ORKA-002 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE1 | SAR447971 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE1 | Soquelitinib |
Tibulizumab is an investigational monoclonal antibody developed by Zura Bio Limited for immune-mediated skin and connective tissue diseases. It is being studied in Phase 2 clinical trials for hidradenitis suppurativa and systemic sclerosis. It is a dual-target inhibitor directed at IL17A and TNFSF13B.
Tibulizumab targets IL17A and TNFSF13B, and it acts as an inhibitor of both. By binding these two targets, the monoclonal antibody is designed to interfere with the inflammatory signaling pathways in which IL17A and TNFSF13B participate. This dual-target profile is the basis for its study in inflammatory skin and fibrotic conditions.
Tibulizumab is being studied for hidradenitis suppurativa and systemic sclerosis, also called scleroderma. Both are the focus of its Phase 2 clinical development. It has not been established as a treatment outside of clinical research, and its use in these indications remains investigational.
Tibulizumab is developed by Zura Bio Limited, which trades under the ticker ZURA. The company is running the Phase 2 program for the antibody in hidradenitis suppurativa and systemic sclerosis across multiple countries, including the United States, Canada, and several European and Latin American sites.
Tibulizumab is in Phase 2 clinical development. It is investigational and is being evaluated in two Phase 2 studies, one in hidradenitis suppurativa and one in systemic sclerosis. Both trials are currently listed as active but not recruiting.
Tibulizumab is being studied in two Phase 2 trials. NCT06993610, the Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense study, enrolls 247 patients with hidradenitis suppurativa. NCT06843239, the TibuSURE study, enrolls 80 patients with systemic sclerosis and scleroderma. Both are randomized, double-blind, placebo-controlled trials in adults aged 18 and older.
Yes, Tibulizumab Dose A is another name used for Tibulizumab. Readers searching under either name are referring to the same monoclonal antibody developed by Zura Bio Limited, a dual inhibitor of IL17A and TNFSF13B under Phase 2 study in hidradenitis suppurativa and systemic sclerosis.